©2026 Incunabulum LLC. All rights reserved. mg Magazine is a registered trademark of Incunabulum LLC. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with prior written permission.
Tag: InnoCan Pharma
Innocan Pharma Closes Private Placement
HERZLIYA, Israel, and CALGARY, AB -- Innocan Pharma Corporation closed a non-brokered private placement offering of 1,193,551 Units at a price of $0.18 per Unit for aggregate gross proceeds...
Innocan Pharma Granted Patent in India
HERZLIYA, Israel, and CALGARY, AB -- Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, received a patent in India covering a prolonged-release...
Innocan Pharma’s LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs
HERZLIYA, Israel, and CALGARY, Alberta -- Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, saw promising results from a multi-year compassionate therapy using...
Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center
HERZLIYA, Israel, and CALGARY, AB -- The FDA's Center for Veterinary Medicine (CVM) has granted Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries,...
FDA Grants Innocan Pharma Meeting Date for LPT-CBD for Chronic Pain
HERZLIYA, Israel, and CALGARY, AB -- Innocan Pharma Corporation is pleased to announce significant advancements in the regulatory process for its Liposome-Cannabidiol (LPT-CBD) technology, which provides...
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial
HERZLIYA, Israel, and ALGARY, AB -- Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, conducted a successful pre-clinical treatment with a liposomal-CBD...
Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After...
HERZLIYA, Israel, and CALGARY, Alberta --
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of...
Innocan Pharma Unveils Groundbreaking Veterinary Breakthroughs at EAVPT 2023 Congress
HERZLIYA, Israel and CALGARY, Alberta --
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF), a leading innovator in pharmaceutical solutions for Human & Animal...
InnoCan Pharma Submits New Patent Applications for Advanced Pain Relief Technology
HERZLIYA, Israel and CALGARY, Alberta --
InnoCan Pharma Corporation (CSE:INNO) ("Innocan Pharma" or the "Company"), a pharmaceutical technology company leveraging its novel cannabis-based therapeutics portfolio of targeted...
Innocan Pharma Reports Success in a Pre-Clinical Trial of a Liposomal-CBD Injection on a...
HERZLIYA, Israel and CALGARY, Alberta --
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a leading pharmaceutical and biotech company,...